--- title: "Razor / Razor-Blade Model, Definition | MedTech Terms" description: "Sell capital equipment at low margin; recurring consumables drive profit. Plain-English Commercialization definition for MedTech teams, with examples and relate" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/razor-razorblade#term", "name": "Razor / Razor-Blade Model", "description": "A business model where capital hardware (the 'razor') is placed at low margin or via no-capital programs to drive recurring sales of consumables, instruments, or single-use components (the 'razor blade'). Surgical robotics, EP mapping, blood-glucose monitoring, and IVD instruments classically follow this model.", "url": "https://medtechterms.com/terms/razor-razorblade", "termCode": "razor-razorblade", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/razor-razorblade#article", "headline": "Razor / Razor-Blade Model", "description": "Sell capital equipment at low margin; recurring consumables drive profit.", "url": "https://medtechterms.com/terms/razor-razorblade", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/razor-razorblade" }, "about": { "@id": "https://medtechterms.com/terms/razor-razorblade#term" }, "articleSection": "Commercialization", "inLanguage": "en", "keywords": "Razor / Razor-Blade Model, Commercialization, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "HBR: razor-blade", "url": "https://hbr.org/", "publisher": { "@type": "Organization", "name": "HBR" } }, { "@type": "CreativeWork", "name": "AHRMM - Healthcare Supply Chain", "url": "https://www.ahrmm.org/", "publisher": { "@type": "Organization", "name": "AHRMM" } }, { "@type": "CreativeWork", "name": "AdvaMed Code of Ethics", "url": "https://www.advamed.org/our-work/code-of-ethics/", "publisher": { "@type": "Organization", "name": "AdvaMed" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/surgical-robotics#term", "name": "Surgical Robotics", "url": "https://medtechterms.com/terms/surgical-robotics" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ivd#term", "name": "In Vitro Diagnostics", "alternateName": "IVD", "url": "https://medtechterms.com/terms/ivd" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Commercialization", "item": "https://medtechterms.com/terms?cat=Commercialization" }, { "@type": "ListItem", "position": 4, "name": "Razor / Razor-Blade Model", "item": "https://medtechterms.com/terms/razor-razorblade" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/razor-razorblade#faq", "mainEntity": [ { "@type": "Question", "name": "How does this model impact post-market surveillance?", "acceptedAnswer": { "@type": "Answer", "text": "Post-market surveillance must encompass both the 'razor' and 'blade' components. Any adverse events or quality issues related to either part, or their interaction, must be tracked and reported per regulations like 21 CFR Part 803 (Medical Device Reporting) or EU MDR Article 87 (Reporting of serious incidents and field safety corrective actions)." } }, { "@type": "Question", "name": "Are 'blades' considered medical devices?", "acceptedAnswer": { "@type": "Answer", "text": "'Blades' are frequently considered medical devices or accessories to medical devices, requiring their own regulatory classification, conformity assessment, and Unique Device Identification (UDI) in line with regulations such as EU MDR Article 2, Definition of 'accessory for a medical device,' and FDA 21 CFR Part 801 (Labeling) and Part 830 (UDI System)." } }, { "@type": "Question", "name": "What cybersecurity considerations arise from this model?", "acceptedAnswer": { "@type": "Answer", "text": "Cybersecurity must address the entire system, including the interfaces between the 'razor' and 'blade' if either component contains software or network connectivity. NIST SP 800-53 and FDA Pre-market Submissions for Management of Cybersecurity in Medical Devices guidance highlight the need for secure design and validation of interconnected components to prevent unauthorized access or manipulation of the MedTech system." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Commercialization](/terms?cat=Commercialization) 6. / 7. Razor / Razor-Blade Model [All terms](/terms) Commercialization [AI / ML in Devices](/ecosystems/ai-ml)[Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) # Razor / Razor-Blade Model Sell capital equipment at low margin; recurring consumables drive profit. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition A business model where capital hardware (the 'razor') is placed at low margin or via no-capital programs to drive recurring sales of consumables, instruments, or single-use components (the 'razor blade'). [Surgical robotics](/terms/surgical-robotics), EP mapping, blood-glucose monitoring, and [IVD](/terms/ivd) instruments classically follow this model. What the regulation says The Razor/Razor-Blade Model, while a commercial strategy, has regulatory implications primarily concerning the compatibility and [interoperability](/terms/interoperability) of the "razor" (device) and "blade" (consumable/accessory) components. Regulations like the EU [MDR](/terms/mdr-reporting) (Regulation (EU) 2017/745) Annex I, [General Safety and Performance Requirements](/terms/gspr) ( [GSPR](/terms/ivdr-gspr)) 12.1 and 12.2, emphasize that devices must be designed and manufactured in such a way as to ensure the compatibility with other devices or accessories. The FDA also addresses this through its guidance on accessory devices and combination products, ensuring that the safety and effectiveness of the system as a whole are maintained, as outlined in 21 CFR Part 820, [Quality System Regulation](/terms/qsr), which requires manufacturers to control product design and its interfaces. ## What this means in practice Pull-through per installed system is the operating metric that matters. CapEx-strapped buyers favor reagent-rental and managed-service variants. ## Examples - A surgical robot (razor) requires proprietary surgical instruments (blades) for each procedure, which are sterilized and single-use, necessitating continuous reordering. - An in-vitro diagnostic (IVD) analyzer (razor) performs tests using specific reagent cartridges (blades) that are designed for that particular instrument. - A continuous glucose monitor (razor) relies on disposable sensors (blades) that require periodic replacement and recalibration for accurate readings. Common pitfalls - • Manufacturers might face scrutiny if the "blade" component is designed to be proprietary in a way that creates an undue barrier to competition or compromises patient safety with alternative "blades." - • Failure to adequately test and validate the "razor" and "blade" components together can lead to regulatory non-compliance and adverse events. - • Changing a "blade" component, even a seemingly minor one, without proper regulatory submission and impact analysis can be considered an unauthorized modification to the MedTech system. - • The supply chain for both "razor" and "blade" components must be robust and controlled, as stockouts could lead to patient care disruptions and regulatory issues. ## Frequently asked questions How does this model impact post-market surveillance? [Post-market surveillance](/terms/post-market-surveillance) must encompass both the 'razor' and 'blade' components. Any adverse events or quality issues related to either part, or their interaction, must be tracked and reported per regulations like 21 CFR Part 803 (Medical Device Reporting) or EU [MDR](/terms/mdr-reporting) Article 87 (Reporting of serious incidents and field safety corrective actions). Are 'blades' considered medical devices? What cybersecurity considerations arise from this model? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Market Segments In Vitro Diagnostics(IVD) Tests performed on biological samples outside the body. ](/terms/ivd)[ Market Segments Surgical Robotics Robotic systems that assist surgeons in performing operations. ](/terms/surgical-robotics) ### More in Commercialization · Same category [ Commercialization AdvaMed Code of Ethics Industry code governing interactions between U.S. medical-device companies and healthcare professionals. ](/terms/advamed-code)[ Commercialization Advisory Board Convening of external experts to advise on strategy or product. ](/terms/advisory-board)[ Commercialization Anti-Kickback Statute(AKS) U.S. criminal statute prohibiting remuneration to induce federal healthcare business. ](/terms/anti-kickback)[ Commercialization Bottom-Up Market Sizing Building market size from procedure volumes × price × penetration. ](/terms/bottom-up-sizing) Cited by Where this term appears across MedTech Terms. Ecosystems (2) - [AI / ML in Devices](/ecosystems/ai-ml) - [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 HBR· 1 AHRMM· 1 AdvaMed· 1 1. [1 HBR: razor-blade Verified HBR · hbr.org ](https://hbr.org/) 2. [2 AHRMM - Healthcare Supply Chain Verified AHRMM · ahrmm.org ](https://www.ahrmm.org/) 3. [3 AdvaMed Code of Ethics Verified AdvaMed · advamed.org ](https://www.advamed.org/our-work/code-of-ethics/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Selling a connected device into health systems? Hospital procurement increasingly requires MDS2, SBOM, and security questionnaires - we help your team answer them confidently. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Commercialization Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=razor-razorblade) Learn in 60 seconds Card Lesson Quiz Sell capital equipment at low margin; recurring consumables drive profit. - · Pull-through per installed system is the operating metric that matters. - · CapEx-strapped buyers favor reagent-rental and managed-service variants. - · Surgical robotics, EP mapping, blood-glucose monitoring, and IVD instruments classically follow this model. Remember this Watch out: Manufacturers might face scrutiny if the "blade" component is designed to be proprietary in a way that creates an undue barrier to competition or compromises patient safety with alternative "blades." Related terms - [Surgical Robotics ](/terms/surgical-robotics) - [In Vitro Diagnostics(IVD) ](/terms/ivd) You may also need Auto-suggested from Commercialization and shared keywords. - [Anti-Kickback Statute(AKS) ](/terms/anti-kickback) - [Managed Service / Reagent Rental ](/terms/managed-service-contract) - [Distributor vs Direct Sales ](/terms/distributor-direct) - [Good Clinical Practice(GCP) ](/terms/gcp) - [Key Opinion Leader(KOL) ](/terms/kol) - [Launch Readiness ](/terms/launch-readiness) [All Commercialization terms](/terms?cat=Commercialization) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)